India's Biopharma Revolution: Unlocking Health Innovation with World Bank Support
A game-changer is brewing in India's biotechnology sector, and it's led by a new generation of entrepreneurs.
Meet Arjun Arunachalam, a trailblazer from Bangalore. His startup has achieved a remarkable feat: developing India's first MRI scanner that matches global standards yet costs significantly less than imported models. Arjun's lightweight, energy-efficient scanners, manufactured by Voxel Grids Innovations, are now aiding cancer treatment in hospitals across Mumbai and Assam, bringing advanced diagnostics within reach for the vast majority of Indians.
Jatin Vimal, another innovator, shares a similar success story. His Chennai-based company, Levim Lifetech, has produced Liraglutide, a biosimilar drug for Type 2 diabetes, at a fraction of the cost of imported versions. This groundbreaking achievement marks India's entry into the complex world of biologics, where drugs are derived from living organisms. Jatin's startup has not only developed this innovative therapy but also managed to break even within a year of production, a feat that has eluded many established companies.
But the innovations don't stop there. Private ventures are also making strides in developing new antibiotics for UTI and pneumonia, while vaccines for dengue, chikungunya, and a deadly strain of malaria are on the horizon, along with the world's first Hepatitis E vaccine. Notably, these vaccines, tailored to Indian strains, will undergo clinical testing across the country, ensuring they cater to India's diverse genetic makeup.
One of the most remarkable developments is the creation of India's first cell therapies for acute lymphoma in adults and children. These therapies address a critical need, as the cost of importing life-saving medications has been a significant barrier. Additionally, research and development are underway for endoscopes, heart valves, dental and bone implants, and stem cell therapy for foot ulcers.
What ties all these breakthroughs together? The National Biopharma Mission (NBM), backed by the World Bank's unique project, Innovate in India for Inclusiveness (i3).
Dr. Jitendra Kumar, Managing Director of BIRAC, the implementing agency, emphasizes, "The National Biopharma Mission is more than a program; it's a catalyst for India's health innovation ecosystem. By connecting discovery with delivery, we're not just making therapies more affordable but also building a resilient biopharma sector that positions India as a leader in equitable healthcare solutions."
India's scientific ecosystem, comprising public research institutions, startups, and private enterprises, is robust and evolving. While collaboration among these stakeholders has been historically limited, BIRAC has been working since 2012 to bridge this gap, fostering stronger and more resilient partnerships. With the World Bank's support, the NBM has been instrumental in advancing biotech research and accelerating the development of biopharmaceuticals since 2017.
One of the Mission's key priorities was strengthening the industry-academia partnership. "Innovation thrives when institutions across sectors collaborate," say Dinesh Nair and Amadou Dem, Senior Health Specialist and Senior Economist, respectively, at the World Bank. "Government-supported breakthroughs occur when public and private entities join forces to leverage their expertise and resources."
The Mission formed Scientific Advisory Groups, bringing together universities, researchers, businesses, and government agencies to share knowledge and approve research that addresses public needs. Dr. Raj K. Shirumalla, Mission Director of the NBM, adds, "Globally, startups are the drivers of innovation, but in India, this wasn't the case due to a lack of funding and support. Startups need nurturing and guidance—financial support, technical advice, regulatory guidance, and access to infrastructure."
The Mission has created the building blocks for such an ecosystem and has become the country's largest source of early-stage funding for the sector. Since 2014, nearly 10,000 bio-based research startups have emerged in India, many of which have benefited directly or indirectly from the Mission's support.
BIRAC has established about 100 incubation centers, providing shared lab facilities where small biotech firms and startups can conduct experiments more affordably and conveniently. These centers, along with 25 specialized research, prototyping, and pilot-scale biomanufacturing facilities set up with NBM support, have created an environment conducive to innovation. Startups have also benefited from expert mentorship, funding, and networking opportunities, all aimed at transforming scientific discoveries into market-ready products. Some of these facilities are located at Venture Center in Pune, C-CAMP in Bengaluru, AMTZ in Vishakhapatnam, IIT Kanpur, and IRSHA in Pune.
Arjun Arunachalam, upon returning to India with a doctorate in electrical engineering and specialization in MRI physics, received initial funding from Tata Trusts to incubate his venture. However, he credits the Rs 12.4 crores he received from the Mission as the catalyst that turned his idea into a reality.
Protecting innovators' intellectual property rights is another critical aspect of the Mission's work. More than 7,000 participants, including 45% women, have been trained in national and global regulations, enabling them to protect their work through Intellectual Property Rights filings.
The Mission has also established seven Regional Technology Transfer Offices, which have collectively handled over 850 intellectual property filings and nearly 120 technology transfers. This protection has encouraged innovators to pursue research, leading to the development of a skilled workforce dedicated to advancing biopharma innovations.
Another focus area is the establishment of clinical trial sites, which are being developed in line with international standards. Some 30 hospital and 10 field sites, with a database of around 800,000 volunteers, have been set up to conduct trials in areas such as cancer, rheumatology, diabetes, and ophthalmology. Over 100 clinical trials have been supported so far, positioning India as a reliable destination for high-quality trials and attracting international partnerships.
Jatin Vimal, the manufacturer of Liraglutide, highlights the impact of the Mission's funding, which covered 85% of his clinical trial costs. He also praises the quarterly scientific advisory and technical review meetings, which provided valuable guidance on the development, regulatory strategy, and project management of his venture, helping him keep costs low and gain faster market access.
One of the Mission's most significant achievements is the development of the world's first DNA-based COVID-19 vaccine, ZyCoV-D, by Zydus Cadila. While Zydus contributed scientific expertise and large-scale manufacturing capabilities, the Mission provided essential funding and technical support.
The Mission is also supporting the development of the chikungunya vaccine by Bharat Biotech, a leading Indian vaccine and bio-therapeutics company. This vaccine, the first of its kind developed and tested in India, has significant market potential both domestically and for export to regions where chikungunya is prevalent, such as Africa, Southeast Asia, and Latin America.
Dr. Badri Patnaik and Dr. Rajashree, leading a team of 20-25 scientists, are confident that the vaccine will be launched soon. They credit the Mission's funding and periodic reviews as instrumental in their progress, along with assistance with regulatory approvals.
India's biopharma future looks promising, but it will require continued public and private support. With sustained investment, progressive regulations, and a strong ecosystem, these innovators can scale up their breakthroughs and make a global impact. India has the potential to not only meet the needs of its people but also become a leader in the biopharmaceutical industry, leaving a lasting mark on global healthcare.
